Abstract:<section class="article-section__content"><h3 class="article-section__sub-title section1"> Background</h3><p>Recent studies reported abnormal alpha‐synuclein deposition in biopsy‐accessible sites of the peripheral nervous system in Parkinson's disease (PD). This has considerable implications for clinical diagnosis. Moreover, if deposition occurs early, it may enable tissue diagnosis of prodromal PD.</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Objective</h3><p>The aim of this study was to develop and test an automated bright‐field immunohistochemical assay of cutaneous pathological alpha‐synuclein deposition in patients with idiopathic rapid eye movement sleep behavior disorder, PD, and atypical parkinsonism and in control subjects.</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Methods</h3><p>For assay development, postmortem skin biopsies were taken from 28 patients with autopsy‐confirmed Lewy body disease and 23 control subjects. Biopsies were stained for pathological alpha‐synuclein in automated stainers using a novel dual‐immunohistochemical assay for serine 129‐phosphorylated alpha‐synuclein and pan‐neuronal marker protein gene product 9.5. After validation, single 3‐mm punch skin biopsies were taken from the cervical 8 paravertebral area from 79 subjects (28 idiopathic rapid eye movement sleep behavior disorder, 20 PD, 10 atypical parkinsonism, and 21 control subjects). Raters blinded to clinical diagnosis assessed the biopsies.</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Results</h3><p>The immunohistochemistry assay differentiated alpha‐synuclein pathology from nonpathological‐appearing alpha‐synuclein using combined phosphatase and protease treatments. Among autopsy samples, 26 of 28 Lewy body samples and none of the 23 controls were positive. Among living subjects, punch biopsies were positive in 23 (82%) subjects with idiopathic rapid eye movement sleep behavior disorder, 14 (70%) subjects with PD, 2 (20%) subjects with atypical parkinsonism, and none (0%) of the control subjects. After a 3‐year follow‐up, eight idiopathic rapid eye movement sleep behavior disorder subjects phenoconverted to defined neurodegenerative syndromes, in accordance with baseline biopsy results.</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Conclusion</h3><p>Even with a single 3‐mm punch biopsy, there is considerable promise for using pathological alpha‐synuclein deposition in skin to diagnose both clinical and prodromal PD. © 2020 International Parkinson and Movement Disorder Society</p></section>

Different Patterns of Exosomal Α‐synuclein Between Parkinson's Disease and Probable Rapid Eye Movement Sleep Behavior Disorder

Different Perivascular Space Burdens in Idiopathic Rapid Eye Movement Sleep Behavior Disorder and Parkinson's Disease.

Central Nervous System-Derived Exosomal Alpha-Synuclein in Serum May Be a Biomarker in Parkinson's Disease.

A Longitudinal Study on Α‐synuclein in Plasma Neuronal Exosomes As a Biomarker for Parkinson’s Disease Development and Progression

α‐Synuclein species in plasma neuron‐derived extracellular vesicles as biomarkers for iRBD

Predictors of Conversion to -Synucleinopathy Diseases in Idiopathic Rapid Eye Movement Sleep Behavior Disorder

Plasma level of alpha-synuclein oligomers as a biomarker for isolated rapid eye movement sleep behavior disorder diagnosis and progression: a prospective cohort study

Biomarkers of conversion to α-synucleinopathy in isolated rapid-eye-movement sleep behaviour disorder

Detection of α-Synuclein in Oral Mucosa by Seed Amplification Assay in Synucleinopathies and Isolated REM Sleep Behavior Disorder

Possible predictors of phenoconversion in isolated REM sleep behaviour disorder: a systematic review and meta-analysis

Association of Concurrent Olfactory Dysfunction and Probable Rapid Eye Movement Sleep Behavior Disorder with Early Parkinson's Disease Progression

Alterations of Brain Structural Network in Parkinson’s Disease with and Without Rapid Eye Movement Sleep Behavior Disorder

Biomarkers of conversion to -synucleinopathy in isolated rapid-eye-movement sleep behaviour disorder

Associations of Sleep Disorders with Cerebrospinal Fluid Α-Synuclein in Prodromal and Early Parkinson’s Disease

Immunohistochemical Detection of Synuclein Pathology in Skin in Idiopathic Rapid Eye Movement Sleep Behavior Disorder and Parkinsonism

Alterations of Peripheral Lymphocyte Subsets in Isolated Rapid Eye Movement Sleep Behavior Disorder

The relationship between serum neurofilament light chain and glial fibrillary acidic protein with the REM sleep behavior disorder subtype of Parkinson's disease

Biofluid Markers and Tissue Biopsies Analyses for the Prodromal and Earliest Phase of Parkinson's Disease

Neuroimaging evidence of glymphatic system dysfunction in possible REM sleep behavior disorder and Parkinson’s disease

Erythrocytic alpha-synuclein as potential biomarker for the differentiation between essential tremor and Parkinson's disease

Impaired Ocular Tracking and Cortical Atrophy in Idiopathic Rapid Eye Movement Sleep Behavior Disorder